Jérémie Nsengimana

Supplementary Figure 8. Topical GC treatment induces comparable systemic leukocyte reduction in parental and GRKO tumor-bearing mice.

Supplementary Figure 7. GCs do not act on immune cells to trigger tumor control.

Supplementary Figure 2. Topical GC treatment of 20967 tumors reduce leukocyte counts systemically.

Supplementary Figure 10. The TGF-β activating function of GARP is required for GC-induced tumor control.

Cluster biomarkers used for cell classification (Fig. 3).

GSEA results for control- or GC-treated 20967 melanomas for the CD8, neutrophil and monocyte clusters related to Fig. 3.

Overlapping DEGs following GC-treatment in vivo and in vitro, leading to development of GC-stimulated gene signature (related to Fig. 4).

Human GC-stimulated gene signature, developed from murine sequencing data (related to Supplementary Table 1).

GSEA results for GC-treated parental and GRKO tumors in vivo related to Fig. 4.

Supplementary Figure 1. The 20967 melanoma model is resistant to immune checkpoint blockade.